Liquidia (LQDA) Insider Khindri Sanjeev Sells $31K of Stock

Sanjeev Khindri, the Chief Development Officer of Liquidia Corporation (LQDA), sold 1,101 shares on October 12, 2026, at a price of $28.48 each, bringing in a total of $31,356. This sale was made under a planned trading arrangement.

Other Institutional Activity in Liquidia Corporation

Blackrock Inc. holds 10,788,586 shares of Liquidia, valued at about $370.6 million after increasing its position by 5,299,329 shares, a 96.5% rise. Farallon Capital Management LLC has 8,365,038 shares, down 290,837 shares or 3.4%. Caligan Partners, LP remains steady with 8,118,892 shares, while Findell Capital Management LLC also holds 3,502,112 shares without any changes. Vanguard Capital Management LLC increased its stake by 212,206 shares, totaling 3,139,183 shares worth approximately $107.8 million.

Liquidia Corporation Stock Down 2.9%

The stock is currently trading around $33.77 as of October 16, 2026, which is significantly below its 50-day moving average of $61.62 and 63.9% below its 52-week high of $93.61. The recent price reflects a challenging period for the company, as it is also trading below its mean price target of $54.38 from analysts.

Recent Earnings

In its trailing twelve months, Liquidia reported revenue of $450.9 million with an earnings per share (EPS) of $1.39. The company has shown a remarkable revenue growth of 1,842.7% year-over-year, alongside a net margin of 30.7% and a return on equity (ROE) of 131.8%. The next earnings report is scheduled for November 3, 2026.

Insider Buying and Selling at Liquidia Corporation

On the same day Khindri sold his shares, other insiders also made trades. Dana Boyle, another officer, sold 5,892 shares at the same price of $28.48, totaling $167,804. Michael Kaseta, the Chief Operating Officer, sold 18,938 shares, while Jason Adair sold 7,301 shares, both at the same price, reflecting a consistent pattern of insider selling.

Analysts Set New Price Targets

On October 1, 2026, Raymond James downgraded Liquidia to an 'Outperform' rating with a target price of $53.00, down from $106.00. BTIG also downgraded the stock to 'Neutral.' Meanwhile, Needham maintained its 'Buy' rating with a target of $72.00, while Wells Fargo downgraded to 'Equal-Weight' with a target of $30.00.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company based in Morrisville, North Carolina. It focuses on developing and commercializing treatments for rare cardiopulmonary diseases. Its lead product is YUTREPIA, used for treating pulmonary arterial hypertension and other related conditions.

Bottom Line

With the next earnings report approaching on November 3, investors will be watching closely for any updates on Liquidia's performance. The recent insider sales and analyst downgrades suggest a cautious outlook for the company in the near term.